When is domperidone indicated, what is the appropriate dosing regimen, and what are its contraindications and common adverse effects?

Domperidone: Clinical Use and Safety Profile

Domperidone should NOT be used as first-line treatment for gastroparesis, but may be considered as a second-line option in patients who have failed or cannot tolerate metoclopramide, particularly those with neurologic adverse effects or movement disorders like Parkinson's disease. 1

Indications

Domperidone is a peripheral dopamine-2 receptor antagonist with prokinetic and antiemetic properties used primarily for:

• Gastroparesis symptoms (nausea, vomiting, early satiety, postprandial fullness) - as second-line therapy 1
• Patients who experienced neurologic adverse effects with metoclopramide 1
• Patients with pre-existing movement disorders (e.g., Parkinson's disease) 1
• Patients declining metoclopramide due to safety concerns 1

The 2025 AGA guidelines give a conditional recommendation AGAINST domperidone as first-line treatment (very low quality evidence), but acknowledge it may be reasonable for patients who prioritize symptom improvement over potential adverse events 1.

Critical Regulatory Status

Domperidone is NOT FDA-approved in the United States for human use. Prescribing requires an expanded access investigational new drug (IND) application from the FDA 1. As of 2025, the current supplier for domperidone under FDA IND is exiting the business and will no longer supply the medication 1.

Dosing Regimen

Standard dosing: 10 mg orally three to four times daily (30-40 mg/day total) 2, 3

• Typical dose: 10 mg TID or QID before meals
• Average maintenance dose in long-term studies: 36 mg/day 2, 3
• Some patients may require titration up to 120 mg/day for refractory symptoms, though this requires intensive cardiac monitoring 4

Duration considerations:

• Initial efficacy assessment at 4-8 weeks 1
• Long-term use is feasible; patients have been maintained on therapy for mean of 7.6 years with continued benefit 3

Contraindications

Absolute contraindications:

• Hypersensitivity to domperidone 5
• History of dangerous arrhythmias
• Baseline prolonged QTc interval (>450 ms in males, >470 ms in females)
• Clinically significant electrolyte disturbances (hypokalemia, hypomagnesemia)
• Presence of prolactinoma
• Gastrointestinal hemorrhage or mechanical obstruction
• Pregnancy and breastfeeding 5

Relative contraindications/high-risk situations:

• Concurrent use of QT-prolonging medications
• Left ventricular dysfunction
• Structural heart disease
• Elderly patients with multiple cardiac risk factors

Mandatory Pre-Treatment and Monitoring Requirements

Before initiating domperidone:

• Serum potassium and magnesium levels 1
• Baseline ECG with QTc interval measurement 1
• Screen for concurrent QT-prolonging medications
• Assess cardiac risk factors

Ongoing monitoring:

• Repeat ECG and electrolytes (potassium, magnesium) at regular intervals while on treatment 1
• Clinical efficacy and adverse effects assessment at 4-8 weeks 1
• Continue monitoring for duration of therapy

Common Adverse Effects

Most frequently reported side effects (from large cohort of 827 patients) 2, 3:

1. Cardiovascular (most concerning):

   • Palpitations/tachycardia (most common cardiac complaint)
   • QTc prolongation (asymptomatic in most cases)
   • Chest pain
   • In one study, 9.5% experienced asymptomatic meaningful QTc prolongation at 120 mg/day 4

2. Gastrointestinal:

   • Diarrhea
   • Abdominal cramping

3. Neurologic:

   • Headache
   • Dizziness
   • Notably, extrapyramidal symptoms are RARE due to minimal blood-brain barrier penetration 6, 7

4. Endocrine:

   • Hyperprolactinemia
   • Galactorrhea/lactation
   • Gynecomastia (rare)

5. Other:

   • Dry mouth
   • Rash

Discontinuation rates: In the largest single-center study, 12% of patients discontinued due to side effects, with 100 of 827 patients (12%) stopping specifically for adverse effects 2, 3. The most common reasons for stopping were palpitations (20 patients), prolonged QTc (13), chest pain (11), and diarrhea (10) 3.

Clinical Efficacy Data

Real-world effectiveness: In a cohort of 115 patients treated with domperidone, 69% reported symptom improvement with mean CPGAS score of 2.7 (between "a little better" and "moderately better"), and 45% were at least moderately improved 2.

Long-term outcomes: Of 827 patients enrolled, 298 (36%) continued treatment for mean of 7.6 years with sustained benefit (CPGAS 2.3, approximately "moderately better") 3.

Symptom-specific improvements: Most pronounced benefits seen in:

• Postprandial fullness
• Nausea
• Vomiting
• Stomach fullness
• Loss of appetite 2, 3

Critical Safety Considerations

Cardiac risk context: While domperidone has been associated with QT prolongation and theoretical risk of sudden cardiac death, the absolute risk appears low when used appropriately. Two thorough QT studies showed minimal to marginal QT effects at therapeutic doses 8. The frequently cited Dutch case-control study reporting increased sudden cardiac death risk was based on only 3 patients out of 1,366 cases and has significant methodological limitations 8.

Key safety principle: The cardiovascular risk is dose-dependent and concentration-dependent, emphasizing the importance of:

• Using lowest effective dose
• Avoiding doses >40 mg/day unless absolutely necessary with intensive monitoring
• Strict adherence to monitoring protocols
• Avoiding concurrent QT-prolonging drugs

Common pitfall: Prescribing domperidone without proper baseline ECG and electrolyte assessment, or failing to monitor these parameters during treatment. This is non-negotiable given the cardiac safety concerns 1.